Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial.
about
Myocardial reperfusion injury: looking beyond primary PCIAutophagy, a process within reperfusion injury: an updateAcute hyperglycemia abolishes ischemic preconditioning by inhibiting Akt phosphorylation: normalizing blood glucose before ischemia restores ischemic preconditioning.High-fat feeding-induced hyperinsulinemia increases cardiac glucose uptake and mitochondrial function despite peripheral insulin resistance.Ultra-acute increase in blood glucose during prehospital phase is associated with worse short-term and long-term survival in ST-elevation myocardial infarction.A community consultation survey to evaluate support for and success of the IMMEDIATE trial.One-year outcomes of out-of-hospital administration of intravenous glucose, insulin, and potassium (GIK) in patients with suspected acute coronary syndromes (from the IMMEDIATE [Immediate Myocardial Metabolic Enhancement During Initial Assessment anNovel adjunctive treatments of myocardial infarction.The vestigial enzyme D-dopachrome tautomerase protects the heart against ischemic injury.RUC-4: a novel αIIbβ3 antagonist for prehospital therapy of myocardial infarctionReperfusion therapy with low-dose insulin or insulin-like growth factor 2; myocardial function and infarct size in a porcine model of ischaemia and reperfusion.Cardiovascular remodelling in coronary artery disease and heart failure.Glucose-insulin-potassium therapy in patients with acute coronary syndrome: a meta-analysis of randomized controlled trials.C-Reactive protein reactions to glucose-insulin-potassium infusion and relations to infarct size in patients with acute coronary syndromes.Genetic modifiers of response to glucose-insulin-potassium (GIK) infusion in acute coronary syndromes and associations with clinical outcomes in the IMMEDIATE trial.How to best manage glycemia and non-glycemia during the time of acute myocardial infarction.Possible increase in insulin resistance and concealed glucose-coupled potassium-lowering mechanisms during acute coronary syndrome documented by covariance structure analysis.Direct Evidence that Myocardial Insulin Resistance following Myocardial Ischemia Contributes to Post-Ischemic Heart FailureMitochondria as a drug target in ischemic heart disease and cardiomyopathyInvolving patients in enrolment decisions for acute myocardial infarction trialsMyocardial ischemia-reperfusion injury: a neglected therapeutic target.A predictive model to identify patients with suspected acute coronary syndromes at high risk of cardiac arrest or in-hospital mortality: An IMMEDIATE Trial sub-study,,In-hospital measurement of left ventricular ejection fraction and one-year outcomes in acute coronary syndromes: results from the IMMEDIATE Trial.Assessing Cardiac Metabolism: A Scientific Statement From the American Heart Association.Usefulness of serum unbound free fatty acid levels to predict death early in patients with ST-segment elevation myocardial infarction (from the Thrombolysis In Myocardial Infarction [TIMI] II trial).Factors associated with longer time to treatment for patients with suspected acute coronary syndromes: a cohort study.Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations.Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology.Key advances in clinical cardiology.Cardioprotection against myocardial reperfusion injury: successes, failures, and perspectives.Pharmacologic therapy that simulates conditioning for cardiac ischemic/reperfusion injury.Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1Cardioprotection and pharmacological therapies in acute myocardial infarction: Challenges in the current era.Stromal derived factor 1α: a chemokine that delivers a two-pronged defence of the myocardium.The clinical burden of type 2 diabetes in patients with acute coronary syndromes: prognosis and implications for short- and long-term management.Remote conditioning the heart overview: translatability and mechanism.ST elevation myocardial infarction: recent advances and updates.Rethinking cardiac metabolism: metabolic cycles to refuel and rebuild the failing heart.Fatty acids and the risk of death during acute myocardial ischaemia.Cardioprotective Effects of Intracoronary Morphine in ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A Prospective, Randomized Trial.
P2860
Q26991482-54381272-CB1B-4A60-96F2-EC6CE5E3B114Q28086932-5EE658A3-A4BB-49BA-9A64-A38D804E8C5CQ30415665-847D7326-16FA-42AD-BB1E-EBF160878073Q33584533-0F668597-F564-4FE7-B085-7E7003B43BD2Q33622028-0C2751EF-BBE9-49A3-8733-4656572AF8ACQ33630734-B5710D3D-7625-4968-8BC4-A5FCAA89B16BQ33705061-1E86B325-2A11-408E-B4F6-8CF34B14A06CQ33812924-F86BD41C-EC0B-4CA1-9130-F691B6D9C78DQ33944140-8B780737-D587-4C56-9330-AF299F080A40Q34267671-B1A5CAAA-DA16-433E-843B-60786D43BC42Q34918663-BD89510A-D55B-4DFC-BFEA-C494F571C048Q35090566-3CFF1027-E8F1-46A0-BEBF-3A28A5617B9AQ35450826-F366CE90-F3C3-41F3-AC24-79C554289166Q35859423-29F7F143-0F8A-4327-9601-9366386C1E2EQ36070345-C38C8E95-8669-42A5-A791-138C860E26EDQ36072601-88B04E23-A920-4897-988B-A80F055DF83AQ36353539-C727BEDD-AAE3-4987-85D5-4FE8E6D5ECB2Q36367130-2E217579-F49E-4233-83AA-94925BE228D2Q36426316-F81079BA-D5F6-468A-8210-C0622125FBD4Q36448976-8B392F34-CAE4-4B23-B181-585EB33EBD33Q36497176-A3FAC39C-72A9-4616-BF66-F2AFB410C764Q36602767-44662956-A941-48A2-88F7-2427F93FDABFQ37150897-D171DD01-FFC4-4AF8-9423-7ED1F58A4910Q37458369-478014B6-B42C-4561-8300-863357962C74Q37483264-5C5D9F87-B841-40DD-8A61-15C6809370B8Q37700946-DF620305-7AFB-4E62-978C-3D0175656B5FQ37738596-B578E326-B2F9-4CE1-BF1A-126215328AC9Q38075417-A3FF01D8-5813-4D49-B910-209488B964E2Q38098440-0081C0B0-666C-4F11-9922-959A39395F23Q38124357-0B9C6EB6-A73F-4016-8659-832A7C7AF365Q38137849-BBB7F51F-E7F5-4D76-A785-F135733E2C1EQ38177382-CBB096C3-372C-40F9-891C-2BB28D6E9F03Q38199493-924FD37C-A86D-4EAB-B255-82630D02D70CQ38202410-69FEE350-296C-422F-8E9E-A88CD5CBC002Q38246002-D9CD6773-FF83-4954-A645-1D9DC04AAE08Q38249023-ED5EB980-1ACB-493E-9974-38D6482DF937Q38263602-2528A113-0758-4F19-809B-1446480DFE5CQ38265521-9C821C6E-113B-456B-9C06-633035BAD795Q38279715-43ED82C4-C168-45B5-A62C-619DB8F11C10Q38378564-EDF3C5E5-85EC-4186-8736-ED91EC171D66
P2860
Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Out-of-hospital administration ...... E randomized controlled trial.
@ast
Out-of-hospital administration ...... E randomized controlled trial.
@en
Out-of-hospital administration ...... E randomized controlled trial.
@nl
type
label
Out-of-hospital administration ...... E randomized controlled trial.
@ast
Out-of-hospital administration ...... E randomized controlled trial.
@en
Out-of-hospital administration ...... E randomized controlled trial.
@nl
prefLabel
Out-of-hospital administration ...... E randomized controlled trial.
@ast
Out-of-hospital administration ...... E randomized controlled trial.
@en
Out-of-hospital administration ...... E randomized controlled trial.
@nl
P2093
P2860
P356
P1476
Out-of-hospital administration ...... E randomized controlled trial.
@en
P2093
Assaad J Sayah
Carin M Van Gelder
Carl S Apstein
Charles E Rackley
Darren A Braude
Delanor D Doyle
Donald J Kosiak
Gert-Paul Walter
Harry P Selker
James E Udelson
P2860
P304
P356
10.1001/JAMA.2012.426
P407
P577
2012-03-27T00:00:00Z